Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in ophthalmic technology, today reported positive three-month postoperative results from Group 1 patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The results met or exceeded expectations for safety, lens delivery, and vision performance, representing a key clinical de-risking milestone as the company advances toward subsequent study phases.
Group 1 patients entered the study with severe visual impairment, with some presenting uncorrected preoperative acuities as poor as 20/250—levels consistent with legal blindness. Post-implantation outcomes demonstrated significant improvements. Dr. Rafael Vázquez, principal investigator of the trial, stated that patients who were classified as legally blind can now read, enjoy everyday life activities, and drive. The impact on their independence and sense of freedom has been remarkable, he added.
Dean Burns, President and CEO of Ocumetics, expressed full confidence in the technology following a detailed review of the data with Dr. Vázquez. The Group 1 data met all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance, successfully achieving the primary objectives required to progress the clinical program. Based on this success, planning for Group 2 surgeries is already underway, with lens and delivery enhancements in development.
The results from Group 1 can be summarized as: safety profile met expectations, visual acuity outcomes met and exceeded expectations, and lens delivery system met expectations. The company continues to apply its rapid win-learn R&D approach, incorporating surgeon feedback in real time to further optimize performance. Refinements to the lens delivery mechanism and multiple lens optimization initiatives have already been implemented based on insights from Group 1.
Ocumetics will host a webinar on Wednesday, February 4, 2026, at 4:00 PM ET to discuss the results and updates on the first-in-human study. More information is available at www.ocumetics.com/webinar.
Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The Ocumetics Lens is designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses by allowing the eye's natural muscle activity to shift focus from distance to near.
